Photodynamic therapy in oncology

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 917-927

  Sibata, C H ^a   Colussi, V C ^a   Oleinick, N L ^a   Kinsella, T J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Oncology; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; ANTHRAQUINONE DERIVATIVE; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; HYPERICIN; LUTETIUM TEXAPHYRIN; NPE 6; PC 4; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PORPHYRIN; PURPURIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RHODAMINE; TALAPORFIN; TEMOPORFIN; TIN ETHYL ETIOPURPURIN; UNCLASSIFIED DRUG; XANTHENE;

ABSORPTION SPECTROSCOPY; ACTINIC KERATOSIS; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CELL KILLING; CLINICAL PROTOCOL; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG PENETRATION; DRUG RETENTION; ENERGY ABSORPTION; EQUIPMENT; ESOPHAGUS CANCER; HUMAN; ILLUMINATION; LIGHT; LUNG CANCER; NONHUMAN; ONCOLOGY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RETINA MACULA DEGENERATION; REVIEW; TISSUE REACTION; TREATMENT INDICATION; TUMOR CELL; UNITED STATES;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; DIHEMATOPORPHYRIN ETHER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ESOPHAGEAL NEOPLASMS; GUIDELINES; HUMANS; INDOLES; LECTINS; LIGHT; LUNG NEOPLASMS; MODELS, CHEMICAL; NEOPLASMS; OXYGEN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 0034864576     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.917     Document Type: Review

References (99)

1. Üeber die Wirkung Fluorescierender Stoffe aut Infusoria
2. Hematoporphyrin derivative for detection and management of cancer
3. Hematoporphyrin Derivative: A possible aid in the diagnosis and therapy of carcinoma of the bladder
4. Photodynamic therapy
5. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies
6. Photodynamic therapy
7. Perspectives of photodynamic therapy for skin diseases
8. Photodynamic therapy
9. Photodynamic therapy: A new concept in medical treatment
10. Definition of type I and type II photosensitized oxidation
11. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: Electron microscopic, histopathologic and biochemical evidence
12. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts
13. Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin
14. An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo
15. Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)-phthalocyanine
16. The photobiology of photodynamic therapy: Cellular targets and mechanisms
17. Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection
18. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4
19. Apoptosis in response to photodynamic therapy: What, where, why, and how
20. Signaling pathways in cell death and survival after photodynamic therapy
21. Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function
22. The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2
23. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy
24. Overexpression of Bcl-X(L) prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA
25. Photodynamic therapy-induced death of MCF-7 human breast cancer cells: A role for caspase-3 in the late steps of apoptosis but not for the critical lethal event
26. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy
27. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo
28. Induction of tumor immunity by photodynamic therapy
29. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors
30. Immunosuppressive effects of silicon phthalocyanine photodynamic therapy
31. Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives
32. Drug distribution. The forgotten relative in clinical pharmacokinetics
33. Determination of Phthalocyanine 4 (Pc 4) Concentration in Tissue by a New Non-Invasive, Site-Specific Spectroscopic Device
34. Non-invasive measurement of chemotherapy drug concentrations in tissue: Preliminary demonstrations of in vivo measurements
35. The measurement of dihematoporphyrin ether concentration in tissue by reflectance spectrophotometry
36. Accuracy of noninvasive in vivo measurements of photosensitizer uptake based on a diffusion model of reflectance spectroscopy
37. On the evolution of some endoscopic light delivery systems for photodynamic therapy
38. Film Dosimetry for Quantitative Flatness and Symmetry of Light Irradiation Devices Used in Photodynamic Therapy
39. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells
40. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy
41. Sequencing of combined hyperthermia and photodynamic therapy
42. Hyperbaric oxygen and photodynamic therapy in tumour-bearing nude mice
43. Enhancement of photodynamic therapy due to hyperbaric hyperoxia: An experimental study of Walker 256 tumors in rats
44. Clinical and preclinical photodynamic therapy
45. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy
46. Chlorins as photosensitizers in biology and medicine
47. The Phthalocyanines: A new class of mammalian cells photosensitizers with a potential for cancer phototherapy
48. New phthalocyanine photosensitizers for photodynamic therapy
49. Current Status of phthalocyanines in the photodynamic therapy of cancer
50. Photodynamic therapy in oncology: Mechanisms and clinical use
51. Phototherapeutic potential of alternative photosensitizers to porphyrins
52. Modified porphyrins, chlorins, phthalocyanines, and purpurins: Second-generation photosensitizers for photodynamic therapy
53. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: A multicenter randomized trial
54. [History of photodynamic therapy-past, present and future]
55. Photodynamic therapy in the management of Barrett's esophagus with dysplasia
56. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation
57. Photodynamic therapy in Barrett's esophagus
58. Photodynamic therapy and the treatment of head and neck neoplasia
59. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies
60. Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer
61. Photodynamic therapy for chest wall recurrence in breast cancer
62. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma
63. Photodynamic therapy of brain tumors
64. Effect of photodynamic therapy on recurrent pituitary adenomas: Clinical phase I/II trial-an early report
65. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: A phase II study
66. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors
67. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges
68. Photodynamic therapy: Successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid
69. 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research
70. Photodynamic Therapy of Oral Cancer: Photosensitization with systemic aminolevulinic acid
71. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy
72. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study
73. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study
74. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: A pilot study
75. Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT): Results of a Phase I/II clinical study conducted at UCSF for the treatment of AIDS-associated cutaneous Kaposi's sarcomas
76. Transperineal photodynamic ablation of the canine prostate
77. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer
78. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: Case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2)
79. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(mhydroxyphenyl)chlorin
80. Interspecies Pharmacokinetics as applied to the "hard drug" photosensiting agent meta (tetrahydroxylchlorin)
81. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: An update
82. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative
83. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: Local control and distant metastasis
84. Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy
85. Photodynamic Therapy Trials with Lutetium Texaphyrin PCI-0123 (Lu-Tex)
86. Photodynamic activity of lutetiumtexaphyrin in a mouse tumor system
87. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: A Phase I clinical study
88. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice
89. Intracavitary photodynamic therapy for malignant pleural mesothelioma
90. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
91. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors
92. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality
93. [Superficial bladder tumors. Pathological and clinical review and presentation of a new diagnostic method: Fluorescence photodetection of transitional epithelial carcinomas based on protoporphyrin IX induction delta-aminolevulinic acid (5-ALA)]
94. Photodynamic therapy in the treatment of Bowen's disease
95. Photodynamic treatment of transplantable bladder tumors in rodents after pretreatment with chloroaluminum tetrasulfophthalocyanine
96. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: A long-term experience
97. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin